| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | - | - | - |
| Operating Income | ¥-22.1B | ¥-13.4B | -65.4% |
| Ordinary Income | ¥-21.5B | ¥-13.0B | -64.8% |
| Net Income | ¥-21.5B | ¥-13.2B | -63.3% |
| ROE | -77.1% | -37.1% | - |
FY2025 consolidated results show significant deterioration in profitability, with operating loss of 2.21B yen (prior year loss of 1.34B yen, YoY -65.4%), ordinary loss of 2.15B yen (prior year loss of 1.30B yen, YoY -64.8%), and net loss attributable to owners of parent of 2.15B yen (prior year loss of 1.32B yen, YoY -63.3%). The company operates as a single-segment gene therapy drug development business with no revenue generation at this pre-commercialization stage, resulting in losses driven primarily by R&D expenses of 1.98B yen and SG&A expenses of 0.23B yen. Total assets decreased to 2.96B yen from 3.69B yen, while total equity declined to 2.79B yen from 3.55B yen, reflecting accumulated losses and cash utilization for operational activities.
The company operates exclusively in gene therapy drug development and remains in the pre-revenue phase, with no sales recorded for the period. The expansion of operating loss by 0.87B yen YoY was driven primarily by intensified R&D investment of 1.98B yen as clinical and non-clinical development activities progressed. SG&A expenses of 0.23B yen represented ongoing infrastructure and administrative costs necessary to support the development pipeline. Non-operating income of 0.08B yen included interest income of 0.004B yen, while non-operating expenses of 0.02B yen included interest expense of 0.003B yen, resulting in minimal net non-operating impact of approximately 0.06B yen. The alignment between ordinary loss of 2.15B yen and net loss of 2.15B yen indicates no material extraordinary items or tax effects during the period. The performance pattern represents revenue absent/profit down, reflecting the company's development-stage status where increasing R&D investment drives expanding losses in pursuit of future product commercialization.
[Profitability] ROE of -77.1% reflects the loss-making structure inherent to pre-revenue development stage operations, with net loss of 2.15B yen eroding shareholder equity. Operating margin cannot be calculated due to absence of revenue, while the R&D intensity ratio of 1.98B yen in R&D expense against 2.96B yen in total assets demonstrates the company's heavy investment orientation. [Cash Quality] Cash and deposits of 28.1B yen cover current liabilities of 1.35B yen by 20.8 times, providing substantial short-term liquidity cushion. [Investment Efficiency] Asset turnover cannot be calculated due to zero revenue, though the concentration of 94.9% of total assets in cash and deposits indicates minimal operational asset deployment at this stage. [Financial Health] Equity ratio of 94.2% represents a highly conservative capital structure, current ratio of 2,145.6% demonstrates exceptional short-term solvency, and debt-to-equity ratio of 0.06 indicates minimal leverage utilization.
Operating cash flow of -2.12B yen represents 0.98 times net loss, indicating that accounting losses closely align with actual cash outflows, confirming the cash-consuming nature of R&D-intensive operations. Investing cash flow of -0.002B yen reflects minimal capital expenditure of 0.003B yen, consistent with the company's focus on expensed R&D rather than capitalized asset investments. Financing cash flow of 1.35B yen provided partial funding to offset operational cash consumption, though specific components of financing activities are not detailed. Free cash flow of -2.12B yen highlights ongoing cash burn requiring external funding or utilization of existing cash reserves. Cash and deposits decreased 7.63B yen from prior period to 28.1B yen, with the decline driven by operational cash consumption partially offset by financing inflows, while the substantial remaining cash balance provides 13.3 months of coverage at current burn rate.
Ordinary loss of 2.15B yen versus operating loss of 2.21B yen shows net non-operating contribution of approximately 0.06B yen, comprising primarily interest income of 0.004B yen and other financial items. Non-operating income represented minimal proportion of overall P&L activity, with the core loss driver being operating activities related to R&D expenditure. The operating cash flow to net income ratio of 0.98 indicates that accounting losses are well-supported by actual cash outflows, with minimal divergence between accrual-based earnings and cash-based performance. The absence of material extraordinary items, impairments, or restructuring charges suggests that reported losses reflect recurring operational reality rather than one-time events. The negative interest coverage ratio of -788.5 reflects profit-based inability to cover interest expense, though the absolute interest burden of 0.003B yen remains minimal relative to cash reserves.
Annual dividend forecast is 0.00 yen with no dividend distribution planned, consistent with the company's pre-revenue development stage and accumulated deficit in retained earnings of -2.04B yen. Payout ratio cannot be calculated due to negative net income. No share buyback activities were disclosed for the period. The absence of shareholder returns reflects prioritization of capital preservation for ongoing R&D activities and clinical development programs, with return policies likely to be reconsidered upon achieving sustained profitability and positive retained earnings.
Clinical development execution risk represents the primary concern, as gene therapy drug development faces inherent uncertainties including trial failures, regulatory delays, or inability to demonstrate sufficient efficacy and safety, with R&D expenses of 1.98B yen producing no guarantee of successful commercialization. Cash runway risk emerges from operating cash flow of -2.12B yen creating annual burn rate that could deplete current cash reserves of 28.1B yen within approximately 13 years at current levels, though acceleration of development activities or clinical expansion could shorten this timeframe significantly. Equity dilution risk arises from probable need for additional financing activities to fund operations until revenue generation, as evidenced by financing cash flow of 1.35B yen during the current period, with future capital raises potentially reducing existing shareholder ownership percentages.
[Industry Position] (Reference - Proprietary Analysis) As a development-stage biotechnology company focused on gene therapy, the company exhibits characteristics typical of pre-revenue pharmaceutical developers, including negative profitability metrics, high cash ratios, and substantial R&D investment relative to asset base. The equity ratio of 94.2% substantially exceeds typical industry medians for biotechnology firms in development stage, reflecting conservative capital structure and limited debt utilization. The concentration of assets in cash holdings of 28.1B yen out of 2.96B yen total assets aligns with industry practice for clinical-stage companies maintaining liquidity to fund multi-year development programs. ROE of -77.1% falls within expected range for pre-revenue developers where losses are structural rather than operational failures. The R&D intensity demonstrated by 1.98B yen in annual R&D expense represents commitment level comparable to peers advancing clinical programs, though specific therapeutic area and development stage determine appropriate comparison benchmarks.
The financial structure reveals a company prioritizing clinical advancement over near-term profitability, with substantial cash reserves of 28.1B yen providing extended runway to execute development programs despite operating losses expanding to 2.21B yen. The operating cash flow to net income ratio of 0.98 confirms that accounting losses accurately reflect cash economics without material timing distortions, indicating transparent financial reporting of development-stage cash consumption. The progressive deterioration in retained earnings from accumulated losses reaching -2.04B yen, combined with zero dividend policy, demonstrates management's focus on capital preservation for R&D investment rather than shareholder distributions, suggesting that value realization depends entirely on successful clinical outcomes and eventual commercialization or partnership monetization.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.